Can sIL2-R differentiate between active sarcoidosis affecting small airways vs uncontrolled asthma and guide treatment with methotrexte vs biologics?

Not exactly, and probably not with enough compelling precision to use it clinically. sIL-2R cannot reliably differentiate active small-airway sarcoidosis from uncontrolled asthma, nor can it independently select methotrexate versus biologic therapy. It is a marker of systemic T-lymphocyte/granuloma ...